-+ 0.00%
-+ 0.00%
-+ 0.00%

ADC Therapeutics Q4 Adj. EPS $(0.09) Beats $(0.27) Estimate, Sales $23.058M Beat $21.390M Estimate

Benzinga·03/10/2026 11:31:09
Listen to the news
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.27) by 66.42 percent. This is a 64 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $23.058 million which beat the analyst consensus estimate of $21.390 million by 7.80 percent. This is a 36.36 percent increase over sales of $16.910 million the same period last year.